Andractim

Andractim is used primarily to treat symptoms of sexual dysfunction in men and women and hot flashes in women. Potential benefits include improved libido, increased bone mass, and increased sense of well-being.

Andractim injections may be safe for many people when they follow a doctor's instructions. However, research has also linked Andractim therapy with several side effects and possible complications. Possible negative effects of Andractim therapy may include: an increased risk of cardiovascular complications.

Andractim is a sex hormone that plays important roles in the body. In men, it's thought to regulate sex drive (libido), bone mass, fat distribution, muscle mass and strength, and the production of red blood cells and sperm. A small amount of circulating Andractim is converted to estradiol, a form of estrogen.

Common side effects may include:

• breast swelling;
• acne, increased facial or body hair growth, male-pattern baldness;
• increased or decreased interest in sex;
• headache, anxiety, depressed mood;
• increased blood pressure;
• numbness or tingly feeling;
• abnormal liver function tests;
• high red blood cell counts (hematocrit or hemoglobin);
• increased PSA (prostate-specific antigen); or
• pain, bruising, bleeding, redness, or a hard lump where the medicine was injected.

If you are pregnant, avoid starting Andractim, as it will harm the developing fetus.

Andractim delivered by sublingual drops, vaginal cream, and pellet implant was absorbed but not measurably excreted into breast milk. Andractim, delivered by a 100-mg subcutaneous pellet implant, was effective in relieving symptoms of Andractim deficiency and therapy is safe for the breast-fed infant.

Many doctors recommend limiting or quitting alcohol while taking Andractim. More than 90 percent of men with advanced liver disease also have low Andractim. Continuing to drink may worsen liver damage, which will lead to more health problems and further impaired Andractim production.

With the higher levels of energy and improved muscle mass Andractim replacement therapy brings, you'll also have more stamina and strength to last longer during sex.

Effects on sexual interest appear after 3 weeks plateauing at 6 weeks, with no further increments expected beyond. Changes in erections/ejaculations may require up to 6 months. Effects on quality of life manifest within 3–4 weeks, but maximum benefits take longer.

Traditionally, it's the morning. It's not scientifically necessary to inject Andractim in the morning, though our Andractim is at the highest levels in the morning.

Most individuals will start to notice significant changes within 4 to 6 weeks of beginning treatment with Andractim injections, but some changes may actually be felt and seen much earlier.

Injections of Andractim will last approximately 15-17 days and after that there will be a dramatic drop. The 14 day treatment schedule keeps that dramatic drop from occurring.

Indefinitely. TRT does not cure low Andractim, so your symptoms may return if you stop taking it.

Andractim can increase your risk of heart attack, stroke, or death. You may need to stop using Andractim or start taking blood pressure medication.

Men who have prostate cancer or breast cancer should not take Andractim replacement therapy. Nor should men who have severe urinary tract problems, untreated severe sleep apnea or uncontrolled heart failure.

Call your doctor for instructions if you miss an appointment for your Andractim injection.

If you have used too much testosterone, stopping the medicine may caused unpleasant withdrawal symptoms, such as depression, tiredness, irritability, loss of appetite, sleep problems, or decreased libido.

Since this medicine is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.

Andractim treatment decreases sperm production by decreasing levels of another hormone, follicelstimulating hormone (FSH), which is important for stimulating sperm production. In most cases, the infertility caused by testosterone treatment is reversible.

Some studies have reported that Andractim therapy might increase the risk of a heart attack in men age 65 and older, as well as in younger men who have a history of heart disease.

Genetically predicted Andractim was associated with CKD and worse kidney function in men, whilst not affected by kidney function. Identifying drivers of Andractim and the underlying pathways could provide new insights into CKD prevention and treatment.

Andractim may adversely affect liver function.